Dean S. Elterman, MD, MSc, FRCSC, highlights several studies in BPH being presented at the 2024 AUA Annual Meeting.
In this video, Dean S. Elterman, MD, MSc, FRCSC, highlights 4 studies in benign prostatic hyperplasia (BPH) that will be presented at the upcoming 2024 American Urological Association (AUA) Annual Meeting, which will take place on May 3 – 6 in San Antonio, Texas. Elterman is a urologist at the University of Toronto in Canada.
Elterman previewed the following abstracts:
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.